PRXL2A

Summary

PRXL2A (peroxiredoxin like 2A, HGNC:28651) is a protein-coding gene on chromosome 10q23.1, encoding Peroxiredoxin-like 2A (Q9BRX8). Involved in redox regulation of the cell.

Enables antioxidant activity. Involved in regulation of osteoclast differentiation. Located in cytoplasm.

Source: NCBI Gene 84293 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 49 total — 1 pathogenic
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_032333

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28651
Approved symbol	PRXL2A
Name	peroxiredoxin like 2A
Location	10q23.1
Locus type	gene with protein product
Status	Approved
Aliases	MGC4248, PAMM, Adrx
Ensembl gene	ENSG00000122378
Ensembl biotype	protein_coding
OMIM	617165
Entrez	84293

Gene structure

Transcript identifiers

Ensembl transcripts: 31 — 31 protein_coding

ENST00000372181, ENST00000372185, ENST00000372187, ENST00000372188, ENST00000606162, ENST00000615554, ENST00000870438, ENST00000870439, ENST00000870440, ENST00000870441, ENST00000870442, ENST00000870443, ENST00000870444, ENST00000870445, ENST00000870446, ENST00000870447, ENST00000870448, ENST00000870449, ENST00000870450, ENST00000923208, ENST00000923209, ENST00000923210, ENST00000923211, ENST00000923212, ENST00000923213, ENST00000960017, ENST00000960018, ENST00000960019, ENST00000960020, ENST00000960021, ENST00000960022

RefSeq mRNA: 6 — MANE Select: NM_032333 NM_001243778, NM_001243779, NM_001243780, NM_001243781, NM_001243782, NM_032333

CCDS: CCDS58089, CCDS7368

Canonical transcript exons

ENST00000606162 — 6 exons

Exon	Start	End
ENSE00000830451	80422417	80422508
ENSE00000830452	80425866	80426006
ENSE00000830453	80427332	80427496
ENSE00001457090	80408551	80408643
ENSE00001457123	80420466	80420645
ENSE00003695025	80431986	80437115

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 99.67.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 47.8669 / max 942.0138, expressed in 1568 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
105854	31.2082	1543
105862	8.2661	708
105855	7.5880	1135
105856	0.3117	57
105859	0.1794	82
105861	0.1470	61
105860	0.0940	54
105858	0.0725	41

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pigmented layer of retina	UBERON:0001782	99.67	gold quality
corpus epididymis	UBERON:0004359	99.63	gold quality
left ventricle myocardium	UBERON:0006566	99.52	gold quality
upper leg skin	UBERON:0004262	99.51	gold quality
kidney epithelium	UBERON:0004819	99.48	gold quality
ileal mucosa	UBERON:0000331	99.42	gold quality
jejunal mucosa	UBERON:0000399	99.37	gold quality
upper arm skin	UBERON:0004263	99.30	gold quality
caput epididymis	UBERON:0004358	99.14	gold quality
skin of hip	UBERON:0001554	99.00	gold quality
mammalian vulva	UBERON:0000997	98.99	gold quality
cardiac muscle of right atrium	UBERON:0003379	98.98	gold quality
postcentral gyrus	UBERON:0002581	98.97	gold quality
parietal lobe	UBERON:0001872	98.93	gold quality
cauda epididymis	UBERON:0004360	98.87	gold quality
adipose tissue	UBERON:0001013	98.85	gold quality
lateral nuclear group of thalamus	UBERON:0002736	98.83	gold quality
subcutaneous adipose tissue	UBERON:0002190	98.73	gold quality
superior frontal gyrus	UBERON:0002661	98.73	gold quality
pons	UBERON:0000988	98.69	gold quality
superior vestibular nucleus	UBERON:0007227	98.68	gold quality
renal medulla	UBERON:0000362	98.62	gold quality
dorsal root ganglion	UBERON:0000044	98.60	gold quality
myocardium	UBERON:0002349	98.56	gold quality
gingiva	UBERON:0001828	98.52	gold quality
gingival epithelium	UBERON:0001949	98.51	gold quality
Brodmann (1909) area 46	UBERON:0006483	98.50	gold quality
lateral globus pallidus	UBERON:0002476	98.49	gold quality
entorhinal cortex	UBERON:0002728	98.48	gold quality
nucleus accumbens	UBERON:0001882	98.44	gold quality

Single-cell (SCXA)

Detected in 14 experiment(s), a significant marker in 10.

Experiment	Marker?	Max mean expression
E-HCAD-23	yes	2236.76
E-GEOD-114530	yes	952.74
E-HCAD-10	yes	611.62
E-CURD-114	yes	72.52
E-MTAB-7316	yes	32.81
E-MTAB-6701	yes	18.62
E-CURD-112	yes	12.81
E-MTAB-7249	yes	11.01
E-MTAB-8410	yes	8.90
E-MTAB-10283	no	890.31
E-MTAB-8271	no	819.44
E-MTAB-6142	no	119.43
E-MTAB-10137	no	7.11
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR1I2

miRNA regulators (miRDB)

45 targeting PRXL2A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-7845-5P	99.88	64.88	771
HSA-MIR-489-3P	99.80	66.46	839
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-3913-3P	99.74	66.53	938
HSA-MIR-586	99.65	70.40	2051
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-3942-3P	99.57	69.03	2854
HSA-MIR-4489	99.50	65.56	785
HSA-MIR-147B-5P	99.45	70.62	2432
HSA-MIR-4762-3P	99.43	69.72	2363
HSA-MIR-125A-5P	99.36	70.59	1640
HSA-MIR-125B-5P	99.36	70.36	1662
HSA-MIR-32-3P	99.36	68.20	2517
HSA-MIR-4777-5P	99.33	67.53	1148

Literature-anchored findings (GeneRIF, showing 5)

• The PAMM is a redox regulatory protein that modulates osteoclast differentiation in vitro. PAMM expression may affect bone resorption in vivo and help to maintain bone mass. (PMID:19951071)
• Antioxidant stress induces PAMM mRNA expression in human peripheral blood mononuclear cells . (PMID:26402163)
• results suggest that adipocyte-derived PAMM may suppress macrophage activation by inhibiting MAPK signalling pathway. (PMID:26438880)
• this study has pinpointed novel clues demonstrating that downregulation of miR-125b suppressor underlies upregulation of PRXL2A in OSCC, and this then protects the affected tumor cells from oxidative stress. (PMID:30785086)
• FAM213A is linked to prognostic significance in acute myeloid leukemia through regulation of oxidative stress and myelopoiesis. (PMID:32124993)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Prxl2a	ENSMUSG00000021792
rattus_norvegicus	Prxl2a	ENSRNOG00000011140

Protein

Protein identifiers

Peroxiredoxin-like 2A — Q9BRX8 (reviewed: Q9BRX8)

Alternative names: Peroxiredoxin-like 2 activated in M-CSF stimulated monocytes, Redox-regulatory protein FAM213A

All UniProt accessions (1): Q9BRX8

UniProt curated annotations — full annotation on UniProt →

Function. Involved in redox regulation of the cell. Acts as an antioxidant. Inhibits TNFSF11-induced NFKB1 and JUN activation and osteoclast differentiation. May affect bone resorption and help to maintain bone mass. Acts as a negative regulator of macrophage-mediated inflammation by inhibiting macrophage production of inflammatory cytokines, probably through suppression of the MAPK signaling pathway.

Subcellular location. Cytoplasm. Secreted.

Tissue specificity. Expressed in CSF1 and TNFSF11-stimulated CD14(+) peripheral blood mononuclear cells (PBMCs).

Induction. Up-regulated by CSF1 in peripheral blood mononuclear cells (PBMCs). This induction is reduced in the presence of TNFSF11.

Miscellaneous. The active site cysteines correspond to the redox-active cysteines of peroxiredoxins.

Similarity. Belongs to the peroxiredoxin-like PRXL2 family. PRXL2A subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9BRX8-1	1	yes
Q9BRX8-2	2

RefSeq proteins (6): NP_001230707, NP_001230708, NP_001230709, NP_001230710, NP_001230711, NP_115709* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR032801	PXL2A/B/C	Family

Pfam: PF13911

UniProt features (9 total): active site 2, mutagenesis site 2, sequence conflict 2, chain 1, region of interest 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BRX8-F1	88.27	0.65

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 85 (redox-active); 88 (redox-active)

Mutagenesis-validated functional residues (2):

Position	Phenotype
85	decrease of about 38% in antioxidant activity in tnfsf11-stimulated osteoclasts and reduced inhibition of tnfsf11-induce
88	decrease of about 125% in antioxidant activity in tnfsf11-stimulated osteoclasts and reduced inhibition of tnfsf11-induc

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 181 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_OSTEOCLAST_DIFFERENTIATION, GCM_GSPT1, LINDGREN_BLADDER_CANCER_CLUSTER_3_DN, GOBP_MYELOID_LEUKOCYTE_DIFFERENTIATION, GOBP_REGULATION_OF_LEUKOCYTE_DIFFERENTIATION, GOBP_REGULATION_OF_HEMOPOIESIS, GOBP_CELLULAR_RESPONSE_TO_TOXIC_SUBSTANCE, CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_UP, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6, GOBP_DETOXIFICATION, SANSOM_APC_TARGETS_DN, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, GCM_NF2, GOMF_ANTIOXIDANT_ACTIVITY

GO Biological Process (2): regulation of osteoclast differentiation (GO:0045670), cellular oxidant detoxification (GO:0098869)

GO Molecular Function (1): antioxidant activity (GO:0016209)

GO Cellular Component (2): extracellular region (GO:0005576), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
regulation of myeloid leukocyte differentiation	1
osteoclast differentiation	1
cellular detoxification	1
molecular_function	1
cellular oxidant detoxification	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

526 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PRXL2A	HSP90AB1	P08238	720
PRXL2A	GUSB	P08236	635
PRXL2A	PALM	O75781	524
PRXL2A	GAPDH	P00354	515
PRXL2A	ACTB	P02570	506
PRXL2A	POTEF	A5A3E0	505
PRXL2A	B2M	P01884	450
PRXL2A	GSTO1	P78417	438
PRXL2A	PRXL2C	Q7RTV5	435
PRXL2A	HADHA	P40939	433
PRXL2A	HPRT1	P00492	427
PRXL2A	ACADVL	P49748	425
PRXL2A	ST3GAL4	Q11206	417
PRXL2A	RIDA	P52758	403
PRXL2A	ATP5MK	Q96IX5	400

IntAct

90 interactions, top by confidence:

A	B	Type	Score
HLA-C	HLA-A	psi-mi:“MI:0914”(association)	0.670
NIPAL1	ESYT2	psi-mi:“MI:0914”(association)	0.640
MME	TMEM223	psi-mi:“MI:0914”(association)	0.530
ADGRG5	KLRG2	psi-mi:“MI:0914”(association)	0.530
A4GNT	POTEF	psi-mi:“MI:0914”(association)	0.530
GDPD5	GOLIM4	psi-mi:“MI:0914”(association)	0.530
FAM131B	AURKA	psi-mi:“MI:0914”(association)	0.530
TLR5	MAN1A2	psi-mi:“MI:0914”(association)	0.530
HLA-G	HLA-B	psi-mi:“MI:0914”(association)	0.530
YIPF3	TMEM120B	psi-mi:“MI:0914”(association)	0.530
CSGALNACT2	GOLIM4	psi-mi:“MI:0914”(association)	0.530
CHRND	TPST2	psi-mi:“MI:0914”(association)	0.530
TSPAN5	SC5D	psi-mi:“MI:0914”(association)	0.530
	VAPB	psi-mi:“MI:0914”(association)	0.500
NRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.480
HMGA1	PRXL2A	psi-mi:“MI:0915”(physical association)	0.400
PCNA	PRXL2A	psi-mi:“MI:0915”(physical association)	0.370
PRXL2A	MYCBP2	psi-mi:“MI:0915”(physical association)	0.370
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
K8.1	EXOC5	psi-mi:“MI:0914”(association)	0.350
YIPF3	TMEM223	psi-mi:“MI:0914”(association)	0.350
RTN1	TMEM120B	psi-mi:“MI:0914”(association)	0.350
SLC39A12	POM121C	psi-mi:“MI:0914”(association)	0.350
TMEM30A	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
SLC18A1	LIMK2	psi-mi:“MI:0914”(association)	0.350

BioGRID (126): FAM213A (Affinity Capture-MS), FAM213A (Affinity Capture-MS), FAM213A (Affinity Capture-MS), FAM213A (Affinity Capture-MS), FAM213A (Affinity Capture-MS), FAM213A (Affinity Capture-MS), FAM213A (Affinity Capture-MS), FAM213A (Affinity Capture-MS), FAM213A (Affinity Capture-MS), FAM213A (Affinity Capture-MS), FAM213A (Affinity Capture-MS), FAM213A (Affinity Capture-MS), FAM213A (Affinity Capture-MS), FAM213A (Affinity Capture-MS), FAM213A (Affinity Capture-MS)

ESM2 similar proteins: A0A1D6NER6, A0JPD7, A1D3P4, B0XPV4, B4QL99, B5X9L9, D9IL24, J9RYI6, O13861, O14349, O42411, O42449, O48529, O74482, P06623, P09543, P13233, P18496, P36101, Q05892, Q0V3D6, Q0WNZ5, Q1H537, Q2QEI3, Q2UBI2, Q38932, Q3ZBK2, Q4WJ38, Q5RFD0, Q5YLB4, Q5ZI34, Q641F0, Q6AXX6, Q6CY84, Q6DW73, Q6DW75, Q6FWV2, Q6NV24, Q6PBP3, Q804E1

Diamond homologs: A0JPD7, A9CQL8, C1C416, D3ZVR7, Q3ZBK2, Q58CY6, Q5R7S9, Q5ZI34, Q641F0, Q6AXX6, Q6PBP3, Q8TBF2, Q9BRX8, Q9CYH2, Q9DB60, B5X9L9, Q28IJ3, Q6AZG8, Q6NV24, Q9ZUU2

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 106 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Antigen Presentation: Folding, assembly and peptide loading of class I MHC	5	26.2×	8e-05
Interferon gamma signaling	5	8.4×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

49 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	36
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2574686	GRCh37/hg19 10p13-q26.3(chr10:12829206-135427143)	Pathogenic

SpliceAI

1059 predictions. Top by Δscore:

Variant	Effect	Δscore
10:80420465:GAAAT:G	acceptor_gain	1.0000
10:80420641:GAAGG:G	donor_gain	1.0000
10:80420642:AAGG:A	donor_gain	1.0000
10:80420643:AGG:A	donor_gain	1.0000
10:80420643:AGGG:A	donor_loss	1.0000
10:80420644:GG:G	donor_gain	1.0000
10:80420644:GGG:G	donor_gain	1.0000
10:80420645:GG:G	donor_gain	1.0000
10:80420646:G:GG	donor_gain	1.0000
10:80420647:T:A	donor_loss	1.0000
10:80422415:A:AG	acceptor_gain	1.0000
10:80422416:G:GG	acceptor_gain	1.0000
10:80422505:AGAGG:A	donor_loss	1.0000
10:80422506:GAG:G	donor_gain	1.0000
10:80422507:AGG:A	donor_loss	1.0000
10:80422509:G:GC	donor_loss	1.0000
10:80422510:TGAG:T	donor_loss	1.0000
10:80422511:GAGT:G	donor_loss	1.0000
10:80425860:CTACA:C	acceptor_loss	1.0000
10:80425861:TACA:T	acceptor_loss	1.0000
10:80425863:CAG:C	acceptor_loss	1.0000
10:80425864:A:AG	acceptor_gain	1.0000
10:80425864:A:AT	acceptor_loss	1.0000
10:80425865:G:GG	acceptor_gain	1.0000
10:80425865:GGA:G	acceptor_gain	1.0000
10:80425865:GGAA:G	acceptor_gain	1.0000
10:80426006:GGTG:G	donor_loss	1.0000
10:80426008:T:A	donor_loss	1.0000
10:80427323:A:AG	acceptor_gain	1.0000
10:80427324:C:G	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000031589 (10:80428649 A>G,T), RS1000102857 (10:80417663 A>G), RS1000130282 (10:80428616 C>G), RS1000277654 (10:80421317 G>A), RS1000332835 (10:80415032 T>C), RS1000516217 (10:80410078 G>A), RS1000747451 (10:80416483 T>G), RS1000914453 (10:80414860 C>A,T), RS1000951781 (10:80435288 T>C), RS1000996759 (10:80408857 C>T), RS1001017466 (10:80415399 T>C), RS1001219332 (10:80411962 T>A,C,G), RS1001512326 (10:80415153 G>T), RS1001565268 (10:80417631 A>G), RS1001610428 (10:80405965 G>T)

Disease associations

OMIM: gene MIM:617165 | disease phenotypes: MIM:609625

GenCC curated gene-disease

Mondo (1): distal 10q deletion syndrome (MONDO:0012315)

Orphanet (1): Distal deletion 10q syndrome (Orphanet:96148)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST001725_5	Inflammatory bowel disease	9.000000e-16
GCST004641_28	Borderline personality disorder	5.000000e-06
GCST005542_5	Sarcoidosis (non-Lofgren’s syndrome without extrapulmonary manifestations)	4.000000e-06
GCST006412_111	Intraocular pressure	1.000000e-09
GCST006979_595	Heel bone mineral density	2.000000e-12
GCST007267_122	Systolic blood pressure	2.000000e-10

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004695	intraocular pressure measurement
EFO:0009270	heel bone mineral density
EFO:0006335	systolic blood pressure

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C567182	Chromosome 10q26 Deletion Syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3879824 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 7,994 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1873475	IBRUTINIB	4	7,994

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.05	IC50	900	nM	IBRUTINIB

PubChem BioAssay actives

1 with measured affinity, of 3 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
Ibrutinib	1337177: Inhibition of PF-06658607 binding to recombinant C-terminal FLAG-tagged FAM213A (unknown origin) expressed in HEK293T cells after 1 hr by gel-based ABPP assay	ic50	0.9000	uM

CTD chemical–gene interactions

68 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression	4
Valproic Acid	affects cotreatment, decreases expression, increases expression	4
trichostatin A	affects cotreatment, decreases expression	3
Tetrachlorodibenzodioxin	decreases expression, increases expression	3
bisphenol A	increases expression	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	2
bisphenol S	increases expression	2
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation	2
Dexamethasone	increases expression, affects cotreatment	2
Tretinoin	increases expression	2
Cyclosporine	decreases expression	2
Aflatoxin B1	affects expression, decreases expression	2
aristolochic acid I	increases expression	1
afuresertib	increases expression	1
bisphenol F	increases expression	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
deoxynivalenol	decreases expression	1
sodium arsenate	decreases expression	1
pyrogallol 1,3-dimethyl ether	increases expression, affects cotreatment, affects localization	1
mono-(2-ethylhexyl)phthalate	increases expression	1
potassium chromate(VI)	increases expression	1
cupric chloride	decreases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
chloropicrin	increases expression	1
K 7174	decreases expression	1
ICG 001	increases expression	1
bisphenol B	increases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3877214	Binding	Inhibition of PF-06658607 binding to recombinant C-terminal FLAG-tagged FAM213A (unknown origin) expressed in HEK293T cells after 1 hr by gel-based ABPP assay	Non-kinase targets of protein kinase inhibitors. — Nat Rev Drug Discov

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.